Teens struggling with hallucinations and delusions will receive mobile phone apps that offer brain training and social support — part of a new University of Minnesota research focus that emphasizes non-drug solutions for severe mental disorders.
Testing the apps will be the U's unique contribution to a new federal study of teens and young adults experiencing their first episodes of psychosis.
The U and four other institutions also will be tracking these first-episode patients to see what demographic or lifestyle factors make them prone to mental illness and what factors promote their recovery.
The psychiatric profession needs alternative therapies because, while drugs can treat symptoms, they don't address a patient's levels of cognition and motivation, which play key roles in their recovery, said Dr. Sophia Vinogradov, chairwoman of the U's department of psychiatry.
"Research has shown us that those are the two factors that really are going to determine how a person is going to do over the long haul," she said.
The study, funded by the National Institute of Mental Health, also reflects a pivot by the U away from the industry-funded drug studies that sparked an ethics scandal several years ago in the Department of Psychiatry and Behavioral Sciences and the resignation of its former chairman. Of 130 existing research protocols in the department, Vinogradov said only about five are industry-funded tests of pharmaceutical compounds.
Nationally, the search for the next blockbuster drug has slowed — by one estimate in 2016, psychopharmacological research by large drug firms had declined 70% in the prior decade — and researchers are instead looking for treatments to augment or replace drug therapy.
"It's seen as the catchall and end-all and be-all, and it's not," Vinogradov said.